The use of bisphosphonates is linked to a reduced risk for fragility fractures in patients with polymyalgia rheumatica on ...

The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...

Findings showed secukinumab demonstrated statistically significant and clinically meaningful sustained remission at week 52 vs placebo. Topline data were announced from a phase 3 trial evaluating ...

Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...

More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in ...

For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is ...

Dr. Roach: I was recently diagnosed with polymyalgia rheumatica after weeks of intense muscle pain. I’m a 67-year-old female in otherwise good health. My doctor prescribed prednisone, which ...